Phase 1b study results of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy
Titel:
Phase 1b study results of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy
Auteur:
Smith, David A. Conkling, Paul Richards, Donald A. Flores, Maria Regina C. Nemunaitis, John J. Boyd, Thomas E. Mita, Alain C. de La Bourdonnaye, Guillaume Wages, David Bexon, Alice S.